SCHEMBL4473631

SCHEMBL4473631

CNc1cc[c]c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.44
MAPT P10636 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
USP2 O75604 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
RECQL P46063 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
EGFR P00533 1/20 0.32
PABPC1 P11940 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HTR6 P50406 1/20 0.32
CYP1A2 P05177 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3482992 0.86 IDO1 (0.38) IDO1MAPTTDP1L3MBTL1USP2
SCHEMBL250357 0.80 KEAP1 (0.54) L3MBTL1KDM4EHPGDHSD17B10KMT2A
SCHEMBL6066253 0.79 IDO1 (0.49) IDO1MAPTKDM4EALDH1A1HPGD
SCHEMBL1535641 0.76 MEN1 (0.55) MAPTTDP1L3MBTL1KDM4EALDH1A1
SCHEMBL7407714 0.76 RXFP1 (0.51) IDO1MAPTKDM4EALDH1A1POLB
SCHEMBL11388125 0.75 PABPC1 (0.46) ALDH1A1PABPC1TSHR
SCHEMBL11289604 0.73 GAA (0.53) IDO1MAPTKDM4EALDH1A1POLB
SCHEMBL67474 0.73 CYP1A2 (0.50) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL9778189 0.71 IDO1 (0.73) IDO1MAPTTDP1L3MBTL1USP2
SCHEMBL30336868 0.71 IDO1 (0.73) IDO1MAPTTDP1L3MBTL1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2589631-B1 INK COMPOSITION, INKJET RECORDING METHOD AND COLORED BODY NIPPON KAYAKU KK (JP) 2014-08-20 EP disclosed
US-8741046-B2 Ink composition, inkjet recording method and colored body NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2014-06-03 US disclosed
EP-2589631-A1 INK COMPOSITION, INKJET RECORDING METHOD AND COLORED BODY Nippon Kayaku Kabushiki Kaisha (JP) 2013-05-08 EP disclosed
US-20130101811-A1 INK COMPOSITION, INKJET RECORDING METHOD AND COLORED BODY NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-04-25 US disclosed
US-7521454-B2 Adenine derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-04-21 US disclosed
EP-1386923-B1 NOVEL ADENINE DERIVATIVES DAINIPPON SUMITOMO PHARMA CO (JP) 2008-08-13 EP disclosed
US-20070037832-A1 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-02-15 US disclosed
US-7157465-B2 Adenine derivatives DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) 2007-01-02 US disclosed
CN-1250548-C Novel adenine derivatives SUMITOMO PHARMA (JP) 2006-04-12 CN disclosed
CN-1512992-A Novel adenine derivatives ס����ҩ��ʽ���� 2004-07-14 CN disclosed
US-20040132748-A1 Novel adenne derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-08 US disclosed
EP-1386923-A1 NOVEL ADENINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-02-04 EP disclosed
EP-0304613-B1 BENZOPYRAN DERIVATIVES BASF Aktiengesellschaft (DE) 1991-06-26 EP disclosed
US-4958021-A PRESSURE AND HEAT SENSITIVE RECORDING MATERIALS BASF AKTIENGESELLSCHAFT (DE) 1990-09-18 US disclosed
EP-0304613-A1 Benzopyran derivatives BASF Aktiengesellschaft (DE) 1989-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132748-A1 Novel adenne derivatives IRF3, IFNAR1, STING1 IDO1 13/4885MAPT 1548/4885TDP1 657/4885
US-20070037832-A1 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis IRF3, IFNAR1, IFNG IDO1 39/4885MAPT 859/4885TDP1 1546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.